Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a strong sell rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “Fresenius Medical has outperformed its industry in the past year. The company reconfirmed the mid-term outlook of its ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. Strong performance in the Health Care Products segment holds promise. The company’s recent strategic partnerships also deserve mention. However, dull performance in North America has been a major dampener. The company continues to face significant foreign-exchange headwinds. Further, higher costs related to dialysis services and peritoneal dialysis product business in China are likely to put margins under pressure. Fresenius Medical faces a cutthroat regulatory environment in almost every country in which it operates. The company has to fulfill specific legal requirements that include tough antitrust regulations.”
A number of other brokerages have also recently commented on FMS. DZ Bank restated a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Thursday, April 5th. Royal Bank of Canada restated a neutral rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, May 29th. Finally, Deutsche Bank upgraded Fresenius Medical Care AG & Co. from a hold rating to a buy rating in a research report on Tuesday, April 24th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Fresenius Medical Care AG & Co. currently has a consensus rating of Hold and an average price target of $54.67.
Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings data on Thursday, May 3rd. The company reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.21). The firm had revenue of $3.98 billion for the quarter, compared to the consensus estimate of $4.07 billion. Fresenius Medical Care AG & Co. had a return on equity of 11.09% and a net margin of 7.29%. The firm’s quarterly revenue was down 12.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 EPS. equities analysts expect that Fresenius Medical Care AG & Co. will post 2.63 EPS for the current fiscal year.
The firm also recently announced an annual dividend, which was paid on Monday, June 4th. Shareholders of record on Tuesday, May 22nd were given a $0.436 dividend. This represents a yield of 0.86%. The ex-dividend date of this dividend was Monday, May 21st. Fresenius Medical Care AG & Co.’s dividend payout ratio is presently 19.46%.
A number of institutional investors have recently added to or reduced their stakes in FMS. Thornburg Investment Management Inc. boosted its stake in shares of Fresenius Medical Care AG & Co. by 50.6% during the first quarter. Thornburg Investment Management Inc. now owns 358,302 shares of the company’s stock valued at $18,302,000 after purchasing an additional 120,411 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Fresenius Medical Care AG & Co. by 569.2% in the fourth quarter. Millennium Management LLC now owns 81,277 shares of the company’s stock worth $4,271,000 after acquiring an additional 69,132 shares during the period. Sivik Global Healthcare LLC acquired a new position in shares of Fresenius Medical Care AG & Co. in the first quarter worth approximately $2,554,000. Royal Bank of Canada lifted its stake in shares of Fresenius Medical Care AG & Co. by 5.8% in the first quarter. Royal Bank of Canada now owns 590,198 shares of the company’s stock worth $30,148,000 after acquiring an additional 32,612 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Fresenius Medical Care AG & Co. in the fourth quarter valued at approximately $1,676,000. Hedge funds and other institutional investors own 2.49% of the company’s stock.
Fresenius Medical Care AG & Co. Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.